Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Yehuda Z. Patt"'
Publikováno v:
Liver Cancer. 4:70-83
Background and Aims: Hepatocellular carcinoma (HCC) incidence is expected to rise dramatically over the next decades because of increasing hepatitis C infections and obesity-related comorbidities. However, little information exists regarding the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d3692eca046178571354cab23e5416a
https://doi.org/10.1159/000367729
https://doi.org/10.1159/000367729
Autor:
Emilio P. Araujo‐Mino, Yehuda Z. Patt, M. Houman Fekrazad, Ben J. Liem, Ashwani Rajput, Cristina Murray‐Krezan, Fa-Chyi Lee, Glenory Heywood, Joshua A. Hanson, Pranshu Bansal
Publikováno v:
The Oncologist
Lessons Learned Colorectal cancers exhibit a high level of cyclooxygenase-2 (COX-2) expression with strong preclinical rationale for improved clinical outcomes with COX-2 inhibition. Celecoxib is a COX-2 inhibitor and we have shown that it can be saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9dc618d11b63edee0f79fc161d6e560
https://pubmed.ncbi.nlm.nih.gov/29158365
https://pubmed.ncbi.nlm.nih.gov/29158365
Autor:
Houman Mohammad Fekrazad, Pranshu Bansal, Yehuda Z. Patt, Cristhiam M. Rojas-Hernandez, Fa-Chyi Lee
Publikováno v:
The Oncologist
Lessons Learned There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options. There exists a potential to combine sorafenib with chemotherapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d1f62fd79f9bc7396726ac09c267f8
https://pubmed.ncbi.nlm.nih.gov/28687627
https://pubmed.ncbi.nlm.nih.gov/28687627
Autor:
Jeffrey S. Morris, Sahin Lacin, Prasun K. Jalal, Robert A. Wolff, Ahmed Omar Kaseb, Reham Abdel-Wahab, Harrys A. Torres, Saira Khaderi, John A. Goss, Ernest T. Hawk, Yasmin Abaza, Ahmed S Shalaby, Yehuda Z. Patt, Hesham M. Hassabo, Renato Lenzi, Christopher I. Amos, Alexandria T. Phan, Manal Hassan, David J. Tweardy, Asif Rashid, Donghui Li, Milind Javle, Gehan Botrus, Ju Seog Lee
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 15(11)
Background & Aims Environmental factors have been identified that affect risk of hepatocellular carcinoma (HCC), but little is known about the effects of sex hormones on liver cancer development or outcome. The authors investigated whether menopause
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a7770ed6ff9e6a01364bec86d6d42b
https://pubmed.ncbi.nlm.nih.gov/28579181
https://pubmed.ncbi.nlm.nih.gov/28579181
Autor:
Yehuda Z. Patt, Kim A. Steinberg, Edward J. Bedrick, Waheed Murad, Ruofei Du, Sang Joon Lee, Fa-Chyi Lee, Pranshu Bansal, Ari D. Baron, Mohammed H. Fekrazad, Yanis Boumber
Publikováno v:
Cancer Medicine
Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor (TKI) with known activity against both. We soug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94ef49fc2f93445345427a211fd84a1
https://pubmed.ncbi.nlm.nih.gov/28801995
https://pubmed.ncbi.nlm.nih.gov/28801995
Autor:
Yehuda Z. Patt, Thomas A. Aloia, James L. Abbruzzese, Jean Nicolas Vauthey, Hesham M. Hassabo, Manal M. Hassan, Richard D. Lozano, Junichi Shindoh, Robert E. Roses, Ahmed Kaseb, Steven A. Curley, Giuseppe Zimmitti
Publikováno v:
Cancer. 119:3334-3342
BACKGROUND The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73deed5e7a1eddd1c15a3a2759224898
https://doi.org/10.1002/cncr.28209
https://doi.org/10.1002/cncr.28209
Autor:
Carol J. Etzel, Asif Rashid, James L. Abbruzzese, Curtis J. Wray, Ernest T. Hawk, Jean Nicolas Vauthey, Hashem B. El-Serag, Mohamed A. Shama, Harmeet Kaur, Yehuda Z. Patt, Donghui Li, Hesham M. Hassabo, Margaret R. Spitz, Ping Chang, Mei Liu, Manal M. Hassan, Basmah S. Hassan, Ahmed O. Kaseb, Khalid Soliman, Evelyne M. Loyer, Katherine S. Hale
Publikováno v:
Molecular Carcinogenesis. 52:139-147
Nonalcoholic fatty liver disease (NAFLD) is an emerging epidemic with high prevalence in Western countries. Genome-wide association studies had reported that a variation in the patatin-like phospholipase domain containing 3 (PNPLA3) gene is associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bf9c9277c12c004ca0ec5537e6d1a94
https://doi.org/10.1002/mc.22057
https://doi.org/10.1002/mc.22057
Autor:
Alexandria T. Phan, Robert A. Wolff, Yasmin Abaza, Ahmed Omar Kaseb, Ibrahim Halil Sahin, Jeffrey S. Morris, Yehuda Z. Patt, Ahmed S Shalaby, Manal Hassan, Donghui Li, Kanwal Pratap Singh Raghav, Ernest T. Hawk, Reham Abdel-Wahab
Publikováno v:
Journal of Epidemiological Research. 3
Background: Hepatocellular carcinoma (HCC) has many well-known predisposing factors including viral hepatitis, alcoholconsumption, metabolic syndrome, and cigarette smoking. However, about 30%-40% of patients have no identifiable risk factor, indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d39fa692ce92fd1a31294381a2c2cb21
https://doi.org/10.5430/jer.v3n1p1
https://doi.org/10.5430/jer.v3n1p1
Autor:
Sylvia Hu, Thomas Cartwright, Herbert Hurwitz, Edward McKenna, Ambrose Kwok, Yehuda Z. Patt, Edith P. Mitchell
Publikováno v:
The Oncologist. 17:937-946
Background. Capecitabine administered for 7 days biweekly with oxaliplatin (XELOX) biweekly has been reported to have activity and safety profiles similar to those of standard capecitabine given for 14 days triweekly. Multiple studies have shown that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f6bdfd46217911c4c564a5cf352cbf
https://doi.org/10.1634/theoncologist.2012-0071
https://doi.org/10.1634/theoncologist.2012-0071
Autor:
Mark M. Zalupski, Robert T. Dorr, Yehuda Z. Patt, Evan M. Hersh, Paul Conkling, Peg Davis, Michelle L. Boytim, Manuel Modiano, Steven J. Cohen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:287-294
Imexon is an aziridine-derived iminopyrrolidone which has synergy with gemcitabine in pancreatic cancer cell lines. Gemcitabine is a standard therapy for pancreatic cancer. We performed a phase I trial of imexon and gemcitabine to evaluate safety, do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a9ab975db3448d3083c92c62a13837f
https://doi.org/10.1007/s00280-009-1162-y
https://doi.org/10.1007/s00280-009-1162-y